Hana Pharm Co Ltd (293480) - Net Assets
Based on the latest financial reports, Hana Pharm Co Ltd (293480) has net assets worth ₩331.75 Billion KRW (≈ $224.82 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩446.69 Billion ≈ $302.72 Million USD) and total liabilities (₩114.94 Billion ≈ $77.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 293480 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩331.75 Billion |
| % of Total Assets | 74.27% |
| Annual Growth Rate | 21.21% |
| 5-Year Change | 24.42% |
| 10-Year Change | N/A |
| Growth Volatility | 46.23 |
Hana Pharm Co Ltd - Net Assets Trend (2016–2025)
This chart illustrates how Hana Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Hana Pharm Co Ltd worth.
Annual Net Assets for Hana Pharm Co Ltd (2016–2025)
The table below shows the annual net assets of Hana Pharm Co Ltd from 2016 to 2025. Also explore Hana Pharm Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩313.41 Billion ≈ $212.39 Million |
+1.37% |
| 2024-12-31 | ₩309.18 Billion ≈ $209.52 Million |
+11.22% |
| 2023-12-31 | ₩277.98 Billion ≈ $188.39 Million |
+3.57% |
| 2022-12-31 | ₩268.40 Billion ≈ $181.89 Million |
+6.55% |
| 2021-12-31 | ₩251.90 Billion ≈ $170.71 Million |
+8.40% |
| 2020-12-31 | ₩232.38 Billion ≈ $157.48 Million |
+5.47% |
| 2019-12-31 | ₩220.33 Billion ≈ $149.32 Million |
+7.28% |
| 2018-12-31 | ₩205.39 Billion ≈ $139.19 Million |
+152.63% |
| 2017-12-31 | ₩81.30 Billion ≈ $55.09 Million |
+46.52% |
| 2016-12-31 | ₩55.48 Billion ≈ $37.60 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hana Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 301.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩184.28 Billion | 58.80% |
| Other Components | ₩129.13 Billion | 41.20% |
| Total Equity | ₩313.41 Billion | 100.00% |
Hana Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Hana Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Polytec Holding AG
VI:PYT
|
$98.98 Million |
|
Devyser Diagnostics AB
ST:DVYSR
|
$99.01 Million |
|
NEOWIZ HOLDINGS Corporation
KQ:042420
|
$99.02 Million |
|
Dharmaj Crop Guard Limited
NSE:DHARMAJ
|
$99.09 Million |
|
Canadian Net Real Estate Investment Trust
V:NET-UN
|
$98.94 Million |
|
Amotech Co. Ltd
KQ:052710
|
$98.90 Million |
|
CO2 Energy Transition Corp. Common Stock
NASDAQ:NOEM
|
$98.83 Million |
|
Amica S.A.
WAR:AMC
|
$98.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hana Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 309,176,120,590 to 313,408,799,140, a change of 4,232,678,550 (1.4%).
- Net income of 8,778,007,690 contributed positively to equity growth.
- Dividend payments of 8,822,737,860 reduced retained earnings.
- New share issuances of 3,349,548,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩8.78 Billion | +2.8% |
| Dividends Paid | ₩8.82 Billion | -2.82% |
| Share Issuances | ₩3.35 Billion | +1.07% |
| Other Changes | ₩927.86 Million | +0.3% |
| Total Change | ₩- | 1.37% |
Book Value vs Market Value Analysis
This analysis compares Hana Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.47x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.81x to 0.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩4542.07 | ₩8240.00 | x |
| 2018-12-31 | ₩11597.57 | ₩8240.00 | x |
| 2019-12-31 | ₩12734.16 | ₩8240.00 | x |
| 2020-12-31 | ₩13430.59 | ₩8240.00 | x |
| 2021-12-31 | ₩14561.19 | ₩8240.00 | x |
| 2022-12-31 | ₩15514.73 | ₩8240.00 | x |
| 2023-12-31 | ₩16068.97 | ₩8240.00 | x |
| 2024-12-31 | ₩17871.98 | ₩8240.00 | x |
| 2025-12-31 | ₩17683.79 | ₩8240.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hana Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.67%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.33x
- Recent ROE (2.80%) is below the historical average (13.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 31.42% | 14.00% | 1.09x | 2.07x | ₩11.88 Billion |
| 2017 | 30.03% | 17.44% | 0.98x | 1.75x | ₩16.21 Billion |
| 2018 | 12.74% | 17.12% | 0.63x | 1.18x | ₩5.63 Billion |
| 2019 | 12.85% | 17.01% | 0.63x | 1.19x | ₩6.27 Billion |
| 2020 | 6.41% | 8.40% | 0.64x | 1.19x | ₩-8.35 Billion |
| 2021 | 11.12% | 14.26% | 0.65x | 1.20x | ₩2.82 Billion |
| 2022 | 9.06% | 11.53% | 0.61x | 1.29x | ₩-2.53 Billion |
| 2023 | 8.03% | 9.95% | 0.64x | 1.25x | ₩-5.47 Billion |
| 2024 | 6.87% | 9.43% | 0.59x | 1.24x | ₩-9.67 Billion |
| 2025 | 2.80% | 3.67% | 0.57x | 1.33x | ₩-22.56 Billion |
Industry Comparison
This section compares Hana Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $514,702,171,378
- Average return on equity (ROE) among peers: 2.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hana Pharm Co Ltd (293480) | ₩331.75 Billion | 31.42% | 0.35x | $98.97 Million |
| Dongwha Pharm.Co.Ltd (000020) | $297.40 Billion | 3.39% | 0.25x | $95.24 Million |
| Yuhan Corp. (000100) | $1.65 Trillion | 3.48% | 0.32x | $3.87 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 3.48% | 0.32x | $45.29 Million |
| Yuyu Pharma (000220) | $128.69 Billion | -1.72% | 0.50x | $42.22 Million |
| Yuyu Pharma Inc (000225) | $140.54 Billion | 5.80% | 0.47x | $14.69 Million |
| Yuyu Pharma Inc (000227) | $135.06 Billion | 6.46% | 0.54x | $30.10 Million |
| Ildong Holdings Co Ltd (000230) | $332.95 Billion | 3.56% | 0.86x | $47.00 Million |
| Samil Pharm (000520) | $56.08 Billion | -15.27% | 1.64x | $107.47 Million |
| Donga Socio Holdings (000640) | $580.35 Billion | 10.90% | 0.82x | $405.77 Million |
| Jw Pharmac (001060) | $172.48 Billion | 6.75% | 1.99x | $426.35 Million |
About Hana Pharm Co Ltd
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and an… Read more